Tumor Tissue- versus Plasma-based Genotyping for Selection of Matched Therapy and Impact on Clinical Outcomes in Patients with Metastatic Breast Cancer.

Neelima VidulaAndrzej NiemierkoGiuliana MalvarosaMegan YuenJochen K LennerzA John IafrateSeth A WanderLaura SpringDejan JuricSteven Jay IsakoffJerry YoungerBeverly MoyLeif W EllisenAditya Bardia

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Plasma-based genotyping identified high rates of actionable mutations, which was associated with significant application of matched therapy and better OS in patients with MBC.See related commentary by Rugo and Huppert, p. 3275.

Keyphrases

metastatic breast cancer
high throughput
genome wide
stem cells
gene expression
genetic diversity
mesenchymal stem cells
single cell